Amendment No. 1 to Consulting Agreement, by and between the Corporation and Steven M. Paul, M.D., dated July 9, 2019
AMENDMENT No. 1
This Amendment No. 01 (“Amendment”) is entered into as of July 9, 2019 (the “Amendment Effective Date”) between Steven M. Paul, M.D. (“Company”) and Voyager Therapeutics, Inc. (“Voyager”) and relates to the Agreement referred to below.
WHEREAS, the parties previously entered into a CONSULTING AGREEMENT, effective August 2, 2018 (the “Agreement”); and
WHEREAS, the parties desire to amend the Agreement as set forth herein.
NOW, THEREFORE, in consideration of the covenants and obligations set forth below, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
1.The 1st sentence of Section 2 – Term and Termination shall be amended as set forth below:
“This Agreement will commence on the Effective Date and will expire on August 2, 2020 unless earlier terminated in accordance with this Agreement or extended by mutual written agreement (the “Term”).”
6.This Amendment may be executed and delivered by facsimile or electronically transmitted signature and in two or more counterparts, all of which together shall constitute one and the same instrument. The parties agree that upon being signed and delivered by the parties, this Amendment shall become effective and binding and that such signed copies will constitute evidence of the existence of this Amendment.
[Remainder of this page is intentionally left blank]
SIGNATURE PAGE TO
AMENDMENT NO. 1 TO
IN WITNESS WHEREOF, the parties hereto entered into this Amendment by their duly authorized representatives as of the Effective Date.
VOYAGER THERAPEUTICS, INC.CONSULTANT
By: /s/ G. Andre TurenneBy: /s/ Steve M. Paul, M.D.
Name: G. Andre TurenneName: Steven M. Paul, M.D.
Title: President and CEO